Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • PD-L1 expression and smoke exp...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma

PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma

Bibliographic Details
Main Authors: Chengming Liu, Zhanyu Wang, Qingpeng Zeng, Sufei Zheng, Xiaoli Feng, Qi Xue, Nan Sun, Jie He
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2023-01-01
Series:Genes and Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S2352304222000757
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2352304222000757

Similar Items

  • Adjuvant therapies for resected limited-stage small cell lung cancer
    by: Savvas Lampridis, MD, MSc
    Published: (2021-12-01)
  • KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
    by: Chengming Liu, et al.
    Published: (2022-09-01)
  • Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer
    by: Di Li, et al.
    Published: (2021-09-01)
  • Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
    by: Runsen Jin, et al.
    Published: (2020-08-01)
  • Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
    by: Chengming Liu, et al.
    Published: (2021-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs